- Home
- INMB vs ZTEK Comparison
INMB vs ZTEK Comparison
Compare INMB & ZTEK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INMB | ZTEK |
|---|---|---|
| Founded | 2015 | 2008 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Major Chemicals |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 57.9M | 59.5M |
| IPO Year | 2018 | 2022 |
Fundamental Metrics
Financial Performance| Metric | INMB | ZTEK |
|---|---|---|
| Price | $2.17 | $0.63 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $5.40 | N/A |
| AVG Volume (30 Days) | ★ 354.0K | 131.1K |
| Earning Date | 05-07-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 11.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $50,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 257.14 | N/A |
| 52 Week Low | $1.09 | $0.37 |
| 52 Week High | $2.58 | $1.24 |
Technical Indicators
Market Signals| Indicator | INMB | ZTEK |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 54.68 |
| Support Level | N/A | $0.55 |
| Resistance Level | N/A | $0.67 |
| Average True Range (ATR) | 0.00 | 0.06 |
| MACD | 0.00 | -0.00 |
| Stochastic Oscillator | 0.00 | 41.22 |
Price Performance
Historical ComparisonAbout INMB INmune Bio Inc.
INmune Bio Inc is a clinical stage biotechnology pharmaceutical company focused on developing and commercializing its product candidates to treat diseases where inflammation and immunology cause a dysfunctional immune system contributing to disease. The company's pipeline products include INKmune, XPro1595, and others. It has three product platforms; The CORDStrom product platform, The DN-TNF product platform, and The Natural Killer Cell Priming Platform.
About ZTEK Zentek Ltd.
Zentek Ltd is engaged in developing opportunities in the graphene and related nano-materials industry based on its intellectual property, patents, and Albany graphite. The Company's operating segments are Intellectual Property Development, Biotech, and Albany Project. Intellectual Property Development includes the manufacturing and distribution of graphene-related products. Biotech includes service revenue generated through aptamer technology. The Albany Project includes the exploration and evaluation of assets and mineral exploration activities.